Cidara Therapeutics Statistics
Total Valuation
CDTX has a market cap or net worth of $53.14 million. The enterprise value is $28.77 million.
| Market Cap | 53.14M |
| Enterprise Value | 28.77M |
Important Dates
The last earnings date was Wednesday, May 15, 2024, after market close.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CDTX has 4.56 million shares outstanding. The number of shares has decreased by -10.31% in one year.
| Shares Outstanding | 4.56M |
| Shares Change (YoY) | -10.31% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 7.34% |
| Owned by Institutions (%) | 29.29% |
| Float | 3.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 5.75 |
| PS Ratio | 1.15 |
| Forward PS | 3.57 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.72
| Current Ratio | 0.72 |
| Quick Ratio | 0.55 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 58.82 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -58.10% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $672,145 |
| Profits Per Employee | -$528,493 |
| Employee Count | 69 |
| Asset Turnover | 0.74 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CDTX has paid $443,000 in taxes.
| Income Tax | 443,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.48% in the last 52 weeks. The beta is 1.11, so CDTX's price volatility has been higher than the market average.
| Beta (1Y) | 1.11 |
| 52-Week Price Change | -58.48% |
| 50-Day Moving Average | 14.76 |
| 200-Day Moving Average | 15.86 |
| Relative Strength Index (RSI) | 38.03 |
| Average Volume (30 Days) | 63,558 |
Short Selling Information
The latest short interest is 83,705, so 1.83% of the outstanding shares have been sold short.
| Short Interest | 83,705 |
| Short Previous Month | 163,367 |
| Short % of Shares Out | 1.83% |
| Short % of Float | 2.16% |
| Short Ratio (days to cover) | 0.71 |
Income Statement
In the last 12 months, CDTX had revenue of $46.38 million and -$36.47 million in losses. Loss per share was -$8.08.
| Revenue | 46.38M |
| Gross Profit | 43.29M |
| Operating Income | -38.15M |
| Pretax Income | -36.02M |
| Net Income | -36.47M |
| EBITDA | -35.16M |
| EBIT | -36.65M |
| Loss Per Share | -$8.08 |
Balance Sheet
The company has $29.02 million in cash and $4.65 million in debt, giving a net cash position of $24.37 million or $5.34 per share.
| Cash & Cash Equivalents | 29.02M |
| Total Debt | 4.65M |
| Net Cash | 24.37M |
| Net Cash Per Share | $5.34 |
| Equity / Book Value | -17.78M |
| Book Value Per Share | -3.90 |
| Working Capital | -18.59M |
Cash Flow
In the last 12 months, operating cash flow was -$18.18 million and capital expenditures -$434,000, giving a free cash flow of -$18.61 million.
| Operating Cash Flow | -18.18M |
| Capital Expenditures | -434,000 |
| Free Cash Flow | -18.61M |
| FCF Per Share | -$4.10 |
Margins
Gross margin is 93.35%, with operating and profit margins of -82.26% and -78.63%.
| Gross Margin | 93.35% |
| Operating Margin | -82.26% |
| Pretax Margin | -77.67% |
| Profit Margin | -78.63% |
| EBITDA Margin | -75.81% |
| EBIT Margin | -79.02% |
| FCF Margin | -40.13% |
Dividends & Yields
CDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 10.31% |
| Shareholder Yield | 10.31% |
| Earnings Yield | -68.62% |
| FCF Yield | -35.02% |
Analyst Forecast
The average price target for CDTX is $61.67, which is 450.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $61.67 |
| Price Target Difference | 450.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 12.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 24, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Apr 24, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
CDTX has an Altman Z-Score of -13.38 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.38 |
| Piotroski F-Score | 1 |